News Related to Obefazimod

Related coverage linked through entity extraction aliases.

Abivax Presents First Anti-Fibrotic Evidence for Obefazimod at ECCO 2026

Feb 21, 2026

Abivax announced novel preclinical and clinical data for obefazimod at ECCO 2026, highlighting anti-fibrotic potential in Crohn's disease, favorable safety profile, and rapid onset of symptomatic relief in inflammatory bowel disease patients.

Drug Hunter Highlights Notable Small Molecules from July Through December 2025

Aug 15, 2025

Drug Hunter's monthly molecule selections from July through December 2025 feature innovative small molecule candidates targeting pain, epilepsy, cancer, infectious diseases, and metabolic disorders, including non-opioid pain agents and precision therapies for rare conditions.